Offering biomedical innovators the experience, expertise, and funding required for success.
Through the RCT Ventures program, venture capital is provided to start-up or early-stage companies with technologies that have the potential to become significant biomedical products with a definite competitive edge. Learn more ›
RCT develops and invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics. Many of these life science tools are available from RCT through affordable nonexclusive licensing. Learn more ›
GlaxoSmithKline plc [LSE/NYSE: GSK] today announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor of three recommendations for the use of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention … Learn more